Samyang Biopharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Samyang Biopharm makes products across two main areas: medical devices, including biodegradable surgical sutures and absorbable hemostatic agents used to control bleeding during surgery, and cancer medicines, covering treatments for solid tumors and blood cancers.
Its customers are broadly hospitals, clinics, and healthcare providers. Listed on KOSPI, Korea's main stock exchange, the company's medical-device division accounts for the larger share of its revenue relative to its pharmaceutical division. It also runs an in-house drug-discovery unit focused on a proprietary gene-therapy drug-delivery platform called SENS.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates a dedicated new-drug development division built around its own gene-therapy delivery platform, SENS, which it developed internally.
Samyang Biopharm in five facts
What does Samyang Biopharm do?
Samyang Biopharm makes products across two main areas: medical devices, including biodegradable surgical sutures and absorbable hemostatic agents used to control bleeding during surgery, and cancer medicines, covering treatments for solid tumors and blood cancers.
Where is Samyang Biopharm listed and in which sector?
Samyang Biopharm (Korean name: 삼양바이오팜) trades under KRX code 0120G0 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Samyang Biopharm?
Its market capitalisation was US$256.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Samyang Biopharm's latest annual revenue and operating profit?
For fiscal year 2025, Samyang Biopharm reported revenue of US$21.6M, operating profit of US$2M and net income of US$1.7M, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.